Early Stage Researchers

ESR1

Solvias, Switzerland
SDU, Denmark

ESR1

Optimising drug co-crystal formulation using in vitro dissolution/permeation models

Justus Lange

Roche, Switzerland
UCC,Ireland

ESR2

Modelling drug-excipient solubilisation interactions to predict excipient selection
Profile

Nicolas Pätzmann

Zentiva, Czech Republic

ESR3

Computational tools to predict co-grinding approaches to overcome dissolution rate limited absorption
Profile

Lotte Ejskjær

UCC, Ireland

ESR4

Molecular dynamics simulations to predict drug supersaturation (Dosup) in microemulsion formulations
Profile

Shaida Panbachi

FHNW, Switzerland

ESR5

Novel therapeutic deep eutectic systems (THEDES)
Profile

Egis Zeneli

FHNW, Switzerland

ESR6

Machine learning using supersaturating drug delivery systems
Profile

Kristian Beran​

Janssen, Belgium

ESR7

Comparison of rDCS to the pre-clinical suspension/solution approach for formulation selection
Profile

ESR8

AstraZeneca, Sweden

ESR8

Predicting the dissolution gains and precipitation risks of salt and co-crystal forms of drugs

Shirin Nika Dietrich

NKUA, Greece

ESR9

Development of an in vitro method for evaluating the impact of gastrointestinal (GI) transfer on performance of enabling formulations under fed state conditions
Profile

Paul Vrenken

Bayer, Germany

ESR10

In silico methods for selecting oral formulations and dosing conditions in early clinical studies
Profile

Florentin Lukas Holzem​

SDU, Denmark

ESR11

Integrating in vitro dissolution-permeation data with biopharmaceutical models to predict the in vivo performance of drug formulations
Profile

Malte Bøgh Senniksen

Fraunhofer, Germany

ESR12

Application of an end–to-end, animal-free modelling approach to the development of enabling drug products: focus on amorphous solid dispersions (ASD)
Profile

Felix Paulus

Janssen, Beligum

ESR13

Developing a novel two-stage in vitro lipolysis model to predict impact of digestion on drug absorption from supersaturating formulations
Profile